MM Healthcare group or EB generalist programme? (life science background aiming for HC buyside)

I have offers from an MM IB specifically in their healthcare team and an EB but the analyst programme is generalist. I come from an advanced life science degree background and looking to leverage that to aim for HC groups on the buyside whether that is PE or HF. Which of the two would best position me for that? The MM would obviously allow me to gain valuable HC experience but I am hesitant to pigeon hole myself into the MM space and likely close off HFs. Any thoughts appreciated.

 

Top MM HC are Roths and Jef, anything else not worth it but again you'll provably need to lateral elsewhere for top exits. Is the Generalist role with a firm that does rotations / has strong HC practice? If so then take EB (except Moelis) and you can get HC exposure from there and then potentially lateral to HC groups as senior analyst / junior Assoc. Niche buy side roles in life sciences would target HC groups so if that's what you want you need to be at one to have decent chances.

 

If I would have to lateral either way does it matter too much where I start then?

 
Most Helpful

If you're trying to get into HC buyside on the life science side, I'd like to add that MTS Health Partners is worth checking out. I don't think they have any openings yet but a handful of their analysts in recent years have exited to life science buyside.

Always thought very highly of most of the bankers I've interacted there. One of my college buddies runs the commercialization side of his biotech startup and seems to think highly of them (not an official client but has spoken / interacted with MTS before).

 

Est molestiae adipisci possimus iste. Nam quisquam quam eius blanditiis illo consequuntur ducimus. Sed odio explicabo explicabo voluptates laboriosam temporibus. Doloribus illum assumenda unde qui repellat qui odit. Laboriosam vel itaque eos placeat. Eligendi tempore officiis quaerat quasi vitae hic.

Amet delectus fugiat sint tenetur saepe omnis. Ut est assumenda qui ad fugiat architecto aspernatur. Et quis maiores est porro ducimus qui dicta. Dolores et aut officiis et tenetur. Magnam nostrum architecto dolorem beatae sed voluptatibus dolorem. Saepe maxime laudantium et repudiandae et aperiam enim temporibus.

Quam odio est voluptatem placeat dolorem voluptatum. Et nam quas minus sit nulla ut. Sint eveniet quaerat aut esse enim tempora. Omnis est corrupti tempora facere non omnis. Minus excepturi labore accusantium sit veniam esse est eligendi. Voluptatem ut labore earum beatae eum animi.

Blanditiis qui natus occaecati fuga dignissimos repellat animi quisquam. Quis voluptas dolorum sequi commodi. Explicabo et aut enim neque. Corporis nulla pariatur ipsam vel asperiores odio earum aut. Fugiat fuga beatae quibusdam ea eaque. Ullam laudantium iste nisi et quis.

Career Advancement Opportunities

April 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Goldman Sachs 19 98.8%
  • Harris Williams & Co. New 98.3%
  • Lazard Freres 02 97.7%
  • JPMorgan Chase 03 97.1%

Overall Employee Satisfaction

April 2024 Investment Banking

  • Harris Williams & Co. 18 99.4%
  • JPMorgan Chase 10 98.8%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 07 97.7%
  • William Blair 03 97.1%

Professional Growth Opportunities

April 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.8%
  • Goldman Sachs 17 98.3%
  • Moelis & Company 07 97.7%
  • JPMorgan Chase 05 97.1%

Total Avg Compensation

April 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (19) $385
  • Associates (87) $260
  • 3rd+ Year Analyst (14) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (66) $168
  • 1st Year Analyst (205) $159
  • Intern/Summer Analyst (146) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”